2024-08-23T12:00:00
SALVOVAR phase III trial: Activated in France and Japan => Already 5 patients enrolled !
SALVOVAR is a phase III trial meant to show that densification of the chemotherapy with the weekly dose-dense paclitaxel in patients presenting with an unfavorable KELIM score < 1.0 and a disease not amenable to complete interval debulking surgery could improve their prognosis. For more details : https://salvovar-cms-uploads.s3.fr-par.scw.cloud/e2898237-e03b-4554-85e8-a2440af3e56d.mp4
2023-10-20T12:00:00
Meeting for SALVOVAR project at ESMO 2023
The partners, investigators and investigating groups of SALVOVAR project are invited to join for a face to face meeting at Madrid on October 20th 2023 at 12:00 am for partners and 2 pm for investigators Site: Novotel Madrid Campo de las Naciones (Hotel Novotel Madrid Campo de las Naciones) - Campo De Las Naciones, C. de Ámsterdam, N° 3, 28042 Madrid, Spain Just facing the convention center
2023-09-29T12:00:00
KELIM presented at ESGO 2023 !
Biomarker-Kinetics and KELIM were presented at ESGO 2023 in a session entitled "PARPi for the better or the worse ?"
2023-07-04T12:00:00
KELIM™ prognostic value in the GCIG meta-analysis dataset accepted in EJC
We are pleased to announce that the article about KELIM™ prognostic value in the GCIG meta-analysis dataset written by Pauline Corbaux was accepted for publication in the European Journal of Cancer !